OncoMatch/Clinical Trials/NCT06935708
Intrathecal Morphine Versus Epidural Analgesia for Open Colon Surgery
Is NCT06935708 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Intrathecal Morphine for colorectal carcinoma.
Treatment: Intrathecal Morphine — Effective pain management after abdominal surgery is essential for recovery. This study compares two pain relief methods-intrathecal morphine (a single spinal injection) and continuous epidural analgesia-for patients undergoing open colorectal cancer surgery. The investigators expect intrathecal morphine to provide equal pain relief at rest 24 hours after surgery, while epidural analgesia may be more effective during movement. By 48 to 72 hours, both methods should offer similar pain control. The epidural group may require fewer additional pain medications but could experience more side effects, including a higher risk of low blood pressure and technical difficulties. Additionally, these patients may have a slightly longer hospital stay. In contrast, the intrathecal morphine group may have fewer overall side effects. Despite these differences, patient satisfaction, sleep quality, and recovery are expected to be similar in both groups. By evaluating these methods, this study aims to determine the most effective and safe approach to post-surgical pain management, improving comfort and recovery outcomes for patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ASA 1–3
Lab requirements
Blood counts
abnormal coagulation function (prothrombin time or activated partial prothrombin time above standard laboratory values or INR ≥1.4); thrombocytopenia (platelet count <80×10^9/L)
Cardiac function
bradycardia (pulse <50/min) or conduction block (2nd or 3rd degree) excluded
abnormal coagulation function, defined as prothrombin time or activated partial prothrombin time above standard laboratory values or an international normalised ratio (INR) ≥1.4; or receiving ongoing therapeutic anticoagulation, thrombocytopenia, defined as a platelet count <80×10 9 L-1, bradycardia (pulse <50/min) or with conduction block (2nd or 3rd degree)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify